Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
Orchestra BioMed Holdings, Inc. will participate in the Jefferies Global Healthcare Conference with CEO David Hochman scheduled for a fireside chat on June 4, 2026. The company’s flagship products, AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon, are in pivotal clinical trials and focus on addressing serious health issues like hypertension and atherosclerotic artery disease. Both products have received FDA Breakthrough Device Designations.
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference.